{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:30:33Z","timestamp":1787067033560,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ogla.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T11:38:00Z","timestamp":1572781080000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of Generic versus Original Prostaglandin Analogues in the Treatment of Glaucoma"],"prefix":"10.1016","volume":"3","author":[{"given":"Alvilda T.","family":"Steensberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia O.","family":"M\u00fcllertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-9322","authenticated-orcid":false,"given":"Augusto","family":"Azuara-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-0734","authenticated-orcid":false,"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2019.10.002_bib1","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","article-title":"Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis","volume":"5","author":"Bourne","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.ogla.2019.10.002_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/aos.12203","article-title":"Factors associated with lifetime risk of open-angle glaucoma blindness","volume":"92","author":"Peters","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00002512-200320080-00005","article-title":"Latanoprost: an update of its use in glaucoma and ocular hypertension","volume":"20","author":"Perry","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ogla.2019.10.002_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/aos.13355","article-title":"The physical properties of generic latanoprost ophthalmic solutions are not identical","volume":"95","author":"Kolko","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib9","first-page":"536746","article-title":"A\u00a0patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop","volume":"2012","author":"Takada","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.ogla.2019.10.002_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5005\/jp-journals-10008-1201","article-title":"Evaluation of physical properties of generic and branded travoprost formulations","volume":"10","author":"Wadhwani","year":"2016","journal-title":"J\u00a0Curr Glaucoma Pract"},{"key":"10.1016\/j.ogla.2019.10.002_bib11","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1111\/bph.14024","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ogla.2019.10.002_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083138","article-title":"Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses","volume":"8","author":"Panic","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ogla.2019.10.002_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656566.2012.662219","article-title":"A\u00a0review of the use of latanoprost for glaucoma since its launch","volume":"13","author":"Digiuni","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ogla.2019.10.002_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ogla.2019.10.002_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5301\/ejo.5000041","article-title":"Latanoprost 0.005% test formulation is as effective as Xalatan\u00ae in patients with ocular hypertension and primary open-angle glaucoma","volume":"22","author":"Allaire","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1120672117747030","article-title":"Prospective study comparing Xalatan\u00ae eye drops and two similar generics as to the efficacy and safety profile","volume":"28","author":"Diagourtas","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcjo.2018.04.017","article-title":"Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost","volume":"54","author":"Ta Kim","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0301-4738.30707","article-title":"A\u00a0randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension","volume":"55","author":"Narayanaswamy","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/1440-1681.12329","article-title":"Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same?","volume":"42","author":"Golan","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ogla.2019.10.002_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/IJG.0b013e318259b47c","article-title":"An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension","volume":"22","author":"Digiuni","year":"2013","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2019.10.002_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2012-302245","article-title":"Generic medications in ophthalmology","volume":"97","author":"Zore","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ophtha.2014.11.022","article-title":"Impact of the introduction of generic latanoprost on glaucoma medication adherence","volume":"122","author":"Stein","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2019.10.002_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10792-016-0280-x","article-title":"Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations","volume":"37","author":"Angmo","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib25","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ophtha.2015.06.013","article-title":"Ability of bottle cap color to facilitate accurate patient-physician communication regarding medication identity in patients with glaucoma","volume":"122","author":"Dave","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2019.10.002_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/02713683.2011.631722","article-title":"A\u00a0comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry","volume":"37","author":"Kahook","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ogla.2019.10.002_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/IJG.0000000000000506","article-title":"Squeeze me if you can: variability in force requirements to extract a drop from common glaucoma bottles","volume":"25","author":"Moore","year":"2016","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2019.10.002_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2015.11.021","article-title":"Variation in number of doses, bottle volume, and calculated yearly cost of generic and branded latanoprost for glaucoma","volume":"163","author":"Queen","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2019.10.002_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/02713683.2014.939763","article-title":"Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies","volume":"40","author":"Velpandian","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ogla.2019.10.002_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/IJG.0000000000000301","article-title":"Consensus on outcome measures for glaucoma effectiveness trials: results from a delphi and nominal group technique approaches","volume":"25","author":"Ismail","year":"2016","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2019.10.002_bib31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bjophthalmol-2013-304323","article-title":"Variation of clinical outcomes used in glaucoma randomised controlled trials: a systematic review","volume":"98","author":"Ismail","year":"2014","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419619303035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419619303035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:51:14Z","timestamp":1762887074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419619303035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2589419619303035"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2019.10.002","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Generic versus Original Prostaglandin Analogues in the Treatment of Glaucoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}